Post-earnings recap
Reported
Thu, May 7, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 2.63%, possibly due to optimism about their ongoing clinical trials and product development efforts. The lack of revenue figures and guidance may leave investors cautious moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | N/A | -83.49% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to advancing their pipeline despite the lack of specific guidance.
Management did not provide specific revenue figures or guidance for future quarters.
The focus remains on ongoing clinical trials and product development.